News

The indication for nivolumab as a single agent for the treatment of hepatocellular carcinoma in patients previously treated with sorafenib has been withdrawn from the US market.

The FDA issued a complete response letter to Incyte Corporation in response to the Biologics License Application for the PD-L1 inhibitor, retifanlimab for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have progressed on, or who are intolerant of, platinum-based chemotherapy.

The FDA has granted priority review to the New Drug Application for nab-sirolimus for consideration as a treatment for patients with advanced malignant perivascular epithelioid cell tumors.

Travis Sims, MD, MPH, discusses the impact of homologous recombination deficiency status of clinical and survival outcomes in patients with advanced-stage ovarian cancer.

In an interview, Robert J. Motzer, MD, explained how further results of the CLEAR trial, including health-related QOL data, suggest the benefit of pembrolizumab and lenvatinib in patients with advanced RCC.

Sintilimab in combination with the bevacizumab biosimilar, IBI305, is associated with a significant overall survival and progression-free survival benefit over sorafenib in the first-line setting for the treatment of Chinese patients with unresectable, hepatitis B virus-associated hepatocellular carcinoma.

Eprenetapop combined with azacitidine has shown positive efficacy as post-transplant maintenance therapy for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia treated in a phase 2 study.

Nathan Pennell, MD, PhD, discusses the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.

A phase 3 study has been initiated in order to evaluate the efficacy of the oral MDM2 inhibitor milademetan for the treatment of de-differentiated liposarcoma.

The overall survival benefit of immunotherapy combinations compared with sunitinib for the treatment of patients with metastatic renal cell carcinoma who have favorable risk may differ from those who have intermediate or poor risk, according to a pooled analysis of frontline combination therapy conducted by the FDA.

In an interview with Targeted Oncology, Bradley Monk, MD, FACCOG, FACS, discusses the OUTBACK trial, including the results, strengths, and challenges.

Based on a review of immune checkpoint inhibitor mechanisms of action and clinical trial data, SITC has published a clinical practice guideline, which provides key recommendations for managing immune-related adverse events.

The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.

Debu Tripathy, MD, discusses the use of tucatinib, capecitabine, and trastuzumab for the treatment of patients with HER2-positive breast cancer and leptomeningeal disease in other HER2-positive cancer types.

Adjuvant treatment with atezolizumab led to a significant improvement in disease-free survival versus supportive care in patients with PD-L1–positive non–small cell lung cancer.

The UriFind test that utilizes DNA methylation detection for the diagnosis of bladder cancer has been granted a breakthrough device designation by the FDA.

The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for the treatment of stage 2b to 4 melanoma.

The FDA has granted breakthrough therapy designation to the combination of venetoclax and azacitidine for the treatment of adult patients with previously untreated intermediate-, high- and very high-risk myelodysplastic syndromes.

American Oncology Network, LLC recently announced the appointment of James Gilmore, PharmD, as the organization’s Chief Pharmacy & Procurement Officer.

Eric Nadler, MD, MPP, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment studied in the IMpower133 trial in extensive-stage small cell lung cancer.

Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses the safety profile of ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia.

The first patient has been dosed in the phase 1/2a clinical trial, designed to evaluate LAVA-051- a gamma-delta bispecific gamma-delta T cell engager that activates Vγ9Vδ2 T cells and type 1 natural killer T cells-in those with chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.

The Fox Chase Cancer Center at Temple University in Philadelphia, Pennsylvania has been added as an active trial site by Salarius Pharmaceuticals, Inc. for the ongoing trial of seclidemstat for the treatment of relapsed or refractory Ewing sarcoma and advanced FET-rearranged sarcomas.

A network meta-analysis looking at 4 studies that assessed atezolizumab/bevacizumab compared to lenvatinib showed there was not a statistically significant improvement for patients with unresectable hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma.

In an interview with Targeted Oncology, HEPANOVA EF-30 investigator, Eleni Gikka, MD, provided insight into the use of TTFields in combination with standard of care therapy for patients with advanced hepatocellular carcinoma.

FDA approval has been granted approval to belumosudil for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.

The combination of the ant-PD-1 inhibitor, pembrolizumab plus chemotherapy before surgery continued by pembrolizumab as a single agent led to statistically significant event-free survival result versus neoadjuvant chemotherapy alone in patients with high-risk early-stage triple-negative breast cancer.

For people living with the one-two punch of both HIV and cancer, coordinated care by a multidisciplinary team that can bring extra resources to bear during treatment offers the best chance of a successful outcome.

The investigational anti-TIGIT agent, COM902, has been administered to a patient for the first time as part of a phase 1 clinical trial evaluating COM902 in combination with the anti-PVRIG agent, COM701 in patients with advanced malignancies who have no alternative treatment options.